Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Saros Therapeutics Inc
Profile last edited on: 2/22/2024      CAGE: 9BJR9      UEI: HGU2SLP22BK2

Business Identifier: Developing, and through partnerships commercializing, novel immunotherapies to improve and extend the lives of patients with cancer.
Year Founded
2021
First Award
2023
Latest Award
2023
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1375 W Fulton Street Suite 650
Chicago, IL 60607
   (773) 266-1929
   N/A
   www.sarostx.com
Location: Single
Congr. District: 07
County: Cook

Public Profile

Developer of innate immune activation technology designed to enhance cancer immunotherapy. The company's technology combines with existing immunotherapies and has the potential to enable a safe and more effective immune response against the tumor than with immunotherapy alone.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$1,196,731
Phase II Dollars
$0
Total Awarded
$1,196,731

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
0 1 NIH $1,196,731
Project Title: Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation

Key People / Management

  Matthew Martin -- Co-Founder and CEO

  Richard Johnson -- Co-Founder, VP of Development

  Dominique Kendrick -- Co-Founder Svp of Regulatory Affairs

  James Moon -- Co-Founder Chief Scientific Officer

Company News

There are no news available.